AGXT2 and fatty liver disease: In this study, we (1) determined plasma SDGV, related metabolites, ALT, and the FLI in a large cohort and compared its diagnostic performance for liver fat detection both cross-sectionally and prospectively, (2) we confirmed the importance of DMGV in a second cohort, and (3) investigated the involvement of AGXT2 and its metabolites in a mouse model of fatty liver disease.